Corcept Therapeutics Announces MOMENTUM Study Findings on Hypercortisolism in Resistant Hypertension Patients
New research stratifies endogenous hypercortisolism prevalence by kidney function in resistant hypertension cohort, potentially expanding addressable patient population.
Study Examines Hormone Disorder in Treatment-Resistant Hypertension
Corcept Therapeutics Incorporated (NASDAQ: CORT) announced results from the MOMENTUM Study examining the prevalence of endogenous hypercortisolism in individuals with resistant hypertension, with findings stratified by kidney function. The research, published by DeFronzo et al. in Heart in Diabetes, represents a significant effort to characterize the intersection between cortisol excess and cardiovascular disease in a challenging patient population.
The study's focus on resistant hypertension—defined as high blood pressure that remains uncontrolled despite treatment with multiple medications—addresses a critical unmet medical need. By stratifying results according to kidney function, researchers may provide clinicians with more granular insights into which patient subgroups exhibit higher rates of hypercortisolism, potentially informing screening and treatment protocols.
Implications for Corcept's Commercial Strategy
For Corcept, a company specializing in cortisol modulation therapies, the MOMENTUM Study findings could support efforts to expand the recognized patient population for conditions related to excess cortisol. The company's flagship product, Korlym (mifepristone), is approved for hyperglycemia in Cushing's syndrome patients, and the firm has been working to broaden awareness of cortisol-related disorders across multiple medical specialties.
The research comes as Corcept maintains a market capitalization of approximately $13 billion, with shares closing at $118.32 prior to the announcement. According to MarginX data, the company is expected to report third-quarter 2026 results on November 4, ahead of the October 28 Federal Open Market Committee rate decision.
Recent Corporate Activity
MarginX data shows recent insider transactions by Atabak Mokari, who exercised options for 24,167 shares and 15,833 shares in separate transactions, subsequently selling 28,460 shares. Such activity is routine for executive compensation structures and does not necessarily signal management sentiment about company prospects.
Investors will likely monitor whether the MOMENTUM Study findings translate into expanded clinical adoption or inform future regulatory strategies as Corcept continues developing its cortisol modulation portfolio.
This article was generated by MarginX from public news on 2026-07-30. It is not investment advice.